The care of XXXX with @entity2316 : audit, feedback, and improvement.

@entity1 @entity8 @entity101 @entity6 @entity2316 @entity3528 @entity299 @entity65 @entity165 @entity454
@entity2316 is the commonest cause of @entity454 in the developed world. The quality of care of 152 @entity1 with @entity2316 was assessed at the time of referral to a single nephrologist. The type II @entity6 (62%) were older than the type I @entity6 (38%) (mean 65 years vs. 48 years). The mean duration of @entity6 was 17 years. Significant @entity65 was present in 52%. There was @entity6 in 84% of the type I @entity6 and 53% of the type II @entity6 . Overall, 63% had @entity101 at referral (St Vincent Declaration criteria), untreated in 25%. ACE inhibitors were not prescribed in 48% when no contraindications to their use were present. Glycosylated haemoglobin was > 9.1% in 29%. Twenty were prescribed medications inappropriate to their renal function. Of @entity1 with @entity299 and serum @entity165 > 5.5 mmol/l, 82% were untreated; 82% of @entity1 with @entity3528 were also untreated. At initial referral, many @entity1 ' care was sub-optimal. Referral was too late for adequate preparation for renal replacement therapy in 33%. Following a process of education and feedback of the results to referring practitioners, the timing of referral improved. We emphasize the need for closer co-operation between those managing @entity6 @entity1 with @entity8 to optimize their care.
